News
- Author:
- Andrew D. Bowser
Publish date: May 1, 2018
LAS VEGAS – Fibrates and other peroxisome proliferator-activated receptor agonists are emerging.
News
- Author:
- Andrew D. Bowser
Publish date: May 1, 2018
Fracture risk appears to be higher among IBD patients who use steroids.
News
- Author:
- Andrew D. Bowser
Publish date: April 30, 2018
New guidelines recommend two different treatment regimens, depending on the answers.
News
- Author:
- Andrew D. Bowser
Publish date: April 30, 2018
We’ve come a long way in clinical trial representation of women, but there’s more work to do.
News
- Author:
- Andrew D. Bowser
Publish date: April 30, 2018
LAS VEGAS –
News
- Author:
- Andrew D. Bowser
Publish date: April 27, 2018
The estimated rate of 6-month progression-free survival was 29% overall, though it was 50% in one biomarker-defined patient subset.
News
- Author:
- Andrew D. Bowser
Publish date: April 25, 2018
Moreover, breast symptom scores were worse for whole breast radiation in the study.
News
- Author:
- Andrew D. Bowser
Publish date: April 24, 2018
Significantly more OSA patients with a recent history of stroke experienced an improvement in their Modified Rankin Scale score after using CPAP, c...
News
- Author:
- Andrew D. Bowser
Publish date: April 23, 2018
“Those with MHO may experience a lag in risk while they progress to metabolic syndrome.”
News
- Author:
- Andrew D. Bowser
Publish date: April 23, 2018
Neither crude stroke incidence rates nor regression analysis indicated a link between sickle cell trait in African Americans and stroke.
News
- Author:
- Andrew D. Bowser
Publish date: April 22, 2018
Closed-loop glucose control systems increase the time in normoglycemia for type 1 diabetic patients, but is it enough?
News
- Author:
- Andrew D. Bowser
Publish date: April 18, 2018
Masked hypertension identified by 24-hour monitoring carried the greatest risk of death.
News
- Author:
- Andrew D. Bowser
Publish date: April 18, 2018
Most of the study discontinuations were because of comorbidities, toxicity from prior treatment, or underlying disease factors.
News
- Author:
- Andrew D. Bowser
Publish date: April 17, 2018
Pravastatin may also have a therapeutic advantage in patients with FLT3 mutations.
Video
- Author:
- Andrew D. Bowser
Publish date: April 17, 2018
GLP-1 agonists were associated with a higher risk of adverse events that led to study withdrawal, compared with SGLT2 inhibitors.
